The Lancet, 2020 The Panel on Antiretroviral Guidelines for Adults and Adolescents with HIV and the American Association for the Study of Liver Diseases guidelines for hepatitis C virus treatment suggest that combination therapy for severe acute respiratory syndrome coronavirus 2 infection will outperform single drugs.
Suranjith L. Seneviratne +4 more
+24 more sources
Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions [PDF]
Journal of Pharmacy & Pharmaceutical Sciences, 2021 Purpose: Remdesivir, a drug originally developed against Ebola virus, is currently recommended for patients hospitalized with coronavirus disease of 2019 (COVID-19).
Subrata Deb, Anthony Allen Reeves
doaj +3 more sources
Treatment effect of remdesivir on the mortality of hospitalised COVID-19 patients in Switzerland across different patient groups: a tree-based model analysis [PDF]
Swiss Medical Weekly, 2023 AIMS OF THE STUDY: Remdesivir has shown benefits against COVID-19. However, it remains unclear whether, to what extent, and among whom remdesivir can reduce COVID-19-related mortality. We explored whether the treatment response to remdesivir differed by
Janne Estill +17 more
doaj +5 more sources
Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE Study [PDF]
Infectious Diseases and Therapy, 2023 Introduction In the PINETREE study, early remdesivir treatment reduced risk of coronavirus disease 2019 (COVID-19)-related hospitalizations or all-cause death versus placebo by 87% by day 28 in high-risk, non-hospitalized patients. Here we report results
Samuel M. Brown +17 more
doaj +2 more sources
Treatment of Severe COVID-19 Infection With Remdesivir in Peritoneal Dialysis [PDF]
Journal of Investigative Medicine High Impact Case Reports, 2023 End-stage kidney disease (ESKD) has been shown to be correlated with an increased risk of COVID-19 infection and mortality. Remdesivir is an effective non-EUA U.S.
Ryan Geffin MD +6 more
doaj +3 more sources
Rapid Response to Remdesivir in Hospitalised COVID-19 Patients: A Propensity Score Weighted Multicentre Cohort Study [PDF]
Infectious Diseases and Therapy, 2023 Introduction Remdesivir is a registered treatment for hospitalised patients with COVID-19 that has moderate clinical effectiveness. Anecdotally, some patients’ respiratory insufficiency seemed to recover particularly rapidly after initiation of ...
Emiel Leegwater +19 more
doaj +3 more sources
Is remdesivir the therapeutic answer for COVID-19: a review of current knowledge [PDF]
, 2020 As the world races to find the solution to the COVID-19 pandemic, an investigational agent which has triggered worldwide interest is remdesivir. Though failing clinical trials for treatment of Ebola virus disease, remdesivir has shown efficacy in ...
Ahsan, Marya, Mallick, Ayaz Khurram
core +3 more sources
Remdesivir-induced severe hypoglycemia in an elderly man without diabetes: a case report [PDF]
Journal of Pharmaceutical Health Care and SciencesBackground Remdesivir is recommended to treat hospitalized patients with coronavirus disease 2019 (COVID-19). Remdesivir is known to affect glucose metabolism in individuals with and without diabetes.
Yasunori Nagano +8 more
doaj +2 more sources
Assessing the evidence on remdesivir [PDF]
The Lancet Infectious Diseases, 2021 SCOPUS: le.j ; info:eu-repo/semantics ...
Trøseid, Marius +4 more
openaire +7 more sources